<table>
<thead>
<tr>
<th>CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDITORIAL</strong></td>
</tr>
</tbody>
</table>
| Cancer Discovery at One Year: The Editors’ Interim Analysis  
Lewis C. Cantley, PhD, and José Baselga, MD, PhD, Editors-in-Chief | Tackling Formalin-Fixed, Paraffin-Embedded Tumor Tissue with Next-Generation Sequencing  
C.L. Corless and P.T. Spellman  
Commentary on Wagle et al., p. 82 |
| **IN THIS ISSUE** | **REVIEW** |
| Highlighted research articles  
1 | Exemestane for Breast Cancer Prevention: A Critical Shift?  
A. DeCensi, B.K. Dunn, M. Puntoni, A. Gennari, and L.G. Ford |
| **NEWS IN BRIEF** | **RESEARCH WATCH** |
| Important news stories affecting the community  
4 | Selected highlights of recent articles of exceptional significance from the cancer literature  
9 |
| **NEWS IN DEPTH** | **ONLINE** |
| Q&A: Craig Thompson on Research Joys and Jobs  
6 | For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews. |
| Jobs Wanted: Cancer Research  
7 |  |
| Combinations Go on Trial  
8 |  |
| **RESEARCH WATCH** |  |
| **VIEWS** In The Spotlight |  |
| A Role for ATM in Hereditary Pancreatic Cancer  
J.L. Bakker and J.P. de Winter  
Commentary on Roberts et al., p. 41 |  |
| Dissecting "PI3Kness": The Complexity of Personalized Therapy for Ovarian Cancer  
R.C. Bast Jr and G.B. Mills  
Commentary on Hanahan et al., p. 56 |  |
| The 14-3-3σ Tumor Suppressor Has Multiple Functions in ErbB2-Induced Breast Cancer  
N.E. Hynes and T. Smirnova  
Commentary on Ling et al., p. 68 |  |
|  |  |
RESEARCH ARTICLES

Genomic Complexity and AKT Dependence in Serous Ovarian Cancer ................. 56

Précis: Individualized analyses of the PI3K/AKT and RAS pathways will identify ovarian cancers that may respond to AKT inhibition.

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing .................. 82

Précis: Targeted, sequencing-based profiling of archival tumor samples identifies genetic alterations that can direct personalized therapy.

Loss of the 14-3-3σ Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression ................. 68
C. Ling, V-M-T. Su, D. Zuo, and W.J. Muller

Précis: 14-3-3σ inactivation accelerates formation and promotes metastasis of ErbB2/HER2-induced tumors.

ON THE COVER
Wagle and colleagues describe a method to profile clinically relevant mutations in formalin-fixed, paraffin-embedded tumor samples involving exon capture of frequently mutated or polymorphic genes followed by massively parallel sequencing. This method identifies single-nucleotide variants, insertions, deletions, and copy number alterations overlooked by current genotyping-based methods with high specificity and sensitivity. Identification of such “actionable” genetic alterations that predict response to targeted or conventional cytotoxic therapies has the potential to facilitate individualized cancer treatment in a time- and cost-effective manner. For details, please see the article by Wagle and colleagues on page 82.